Search Results

Displaying Results 1-2 of 2 "'PDCO'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)

Dec 02, 2025, 10:30 ET AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)

dermatitis and pruritus.EMA's Pediatric Committee (PDCO) agrees to AOBiome's PIP with a positive decision on September 10, 2025 and publishes in the EMA website on November 06, 2025, paving the path for development of B244 in the EU.PDCO decision includes granting a topical corticosteroid

More news about: AOBiome Therapeutics

Sep 30, 2025, 07:30 ET Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

PMC10471512. About the Pediatric Committee (PDCO) The Pediatric Committee (PDCO) is the European Medicines Agency's (EMA) scientific committee responsible for activities on medicines for children and

More news about: Acurx Pharmaceuticals, Inc.

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.